Senores Pharmaceuticals Ltd

Senores Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Senores Pharmaceuticals Ltd

₹ 737 -0.73%
12 Mar - close price
senorespharma.com BSE: 544319 NSE: SENORES
About

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]

Key Points

Business Overview:[1]
SPL is a global research-driven pharmaceutical company that develops and manufactures
pharmaceutical products for the Regulated Markets of the US, Canada, and the United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. The company develops and manufactures specialty, underpenetrated, and complex pharmaceutical products. It also manufactures critical care injectables and APIs.

Website BSE NSE
  • Market Cap ₹ 3,372 Cr.
  • Current Price ₹ 737
  • High / Low ₹ 876 / 440
  • Stock P/E 245
  • Book Value ₹ 155
  • Dividend Yield 0.00 %
  • ROCE 2.15 %
  • ROE 0.84 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Stock is trading at 4.75 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 0.99% over last 3 years.
  • Earnings include an other income of Rs.38.8 Cr.
  • Company has high debtors of 243 days.
  • Working capital days have increased from -372 days to 105 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
8.91 10.61 7.48 9.63 9.59 11.86 19.82 35.33 28.76
9.44 8.74 8.26 10.97 12.01 14.60 20.98 33.81 29.69
Operating Profit -0.53 1.87 -0.78 -1.34 -2.42 -2.74 -1.16 1.52 -0.93
OPM % -5.95% 17.62% -10.43% -13.91% -25.23% -23.10% -5.85% 4.30% -3.23%
2.15 5.18 2.45 3.09 7.19 9.25 8.39 11.36 9.78
Interest 0.67 0.73 0.80 0.68 2.70 2.35 1.76 1.58 1.75
Depreciation 0.46 0.66 0.52 0.53 0.75 1.27 1.88 3.65 3.58
Profit before tax 0.49 5.66 0.35 0.54 1.32 2.89 3.59 7.65 3.52
Tax % 59.18% 158.83% 11.43% 44.44% 18.94% 30.45% 24.79% 15.95% 24.72%
0.20 -3.33 0.31 0.30 1.07 2.01 2.70 6.43 2.65
EPS in Rs 0.07 -1.09 0.09 0.09 0.23 0.44 0.59 1.40 0.58
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
8 14 12 34 39 96
7 12 14 34 46 99
Operating Profit 1 1 -2 -0 -7 -3
OPM % 13% 9% -14% -0% -19% -3%
0 1 7 7 22 39
Interest 0 1 2 3 7 7
Depreciation 1 1 1 2 3 10
Profit before tax 0 1 2 2 5 18
Tax % -110% 18% 38% 60% 28%
1 1 1 1 4 14
EPS in Rs 2.21 0.69 1.22 0.27 0.80 3.01
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 42%
TTM: 157%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 76%
TTM: 936%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 28%
Return on Equity
10 Years: %
5 Years: 1%
3 Years: 1%
Last Year: 1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 4 9 10 31 46 46
Reserves 6 25 29 138 662 668
4 15 61 101 103 67
2 7 12 17 23 36
Total Liabilities 15 55 112 286 834 817
2 2 8 24 55 85
CWIP 3 3 11 18 34 12
Investments 1 12 8 82 104 141
9 39 84 162 641 578
Total Assets 15 55 112 286 834 817

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-3 -24 -43 -19 -20
-4 -10 -5 -57 -163
8 34 47 87 533
Net Cash Flow 1 -0 -2 10 349

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 11 226 464 236 243
Inventory Days 31 133 194 121 299
Days Payable 12 269 273 310 452
Cash Conversion Cycle 30 89 385 47 90
Working Capital Days 197 102 -566 -656 105
ROCE % 5% 6% 3% 2%

Insights

In beta
Mar 2023Dec 2024Dec 2025
Annual Installed Capacity (API Manufacturing)
MTPA

Log in to view insights

Please log in to see hidden values.

Login
Approved ANDA Products/Strengths (Regulated Markets)
Number
Approved ANDAs (Regulated Markets)
Number
Approved Products (Emerging Markets)
Number
CDMO/CMO Commercialized Products
Number
Commercialized ANDAs (Regulated Markets)
Number
Pipeline Products/Applications Filed (Emerging Markets)
Number
Revenue Realization per Unit (Emerging Markets)
INR
Annual Installed Capacity (Atlanta OSD Facility)
Million Units
Annual Installed Capacity (Chhatral General Oral Dosage)
Million Units

Shareholding Pattern

Numbers in percentages

11 Recently
Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
45.77% 45.78% 45.78% 45.80% 45.81%
4.25% 4.17% 3.66% 4.28% 3.35%
11.77% 9.66% 9.51% 8.62% 9.32%
38.20% 40.39% 41.03% 41.30% 41.54%
No. of Shareholders 49,51837,65336,38934,91734,401

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls